Seeing a need, taking the lead
by looking further than AHI
Nearly 30% of patients with obstructive sleep apnea (OSA) have insomnia, which is associated with reduced CPAP compliance, worse treatment outcomes, lower quality of life, and serious health issues.2-5
NEW WatchPAT® with SleePATh® is an advanced, multifunctional app with an in-app questionnaire that evaluates insomnia, as well as daytime sleepiness, sleep scheduling, restless leg syndrome, and patient behavior and lifestyle.
With a single-night study, disease severity is misclassified in up to 20% of patients.6
NEW WatchPAT® WatchPAT® ONE-M gives you the flexibility for multi-night testing. Fully disposable to reduce infection risks, with instant results after each night’s test,* it is the WatchPAT® ONE device sleep clinicians trust.
Patients with REM-related OSA have lower, or even normal, AHI scores and report milder daytime symptoms, which can lead to misdiagnosis.7
WatchPAT® 300 and WatchPAT® ONE HSATs are powered by breakthrough PAT® technology, which can detect sleep stages and REM sleep apnea.
When total recording time is used, 20% of cases are misdiagnosed/misclassified.8
With advanced actigraphy that differentiates between wake
and sleep periods, WatchPAT® 300 and WatchPAT® ONE use true sleep time to calculate AHI and RDI.
While obstructive sleep apnea is typically treated with CPAP devices or oral appliances, treatment for central sleep apnea may begin by addressing the underlying health cause.9
The Central PLUS module enables WatchPAT® 300 and WatchPAT® ONE to identify central sleep apnea and percent of sleep time with Cheyne-Stokes respiration.
*Within minutes of test completion.
References: 1. Yalamanchali S, Farajian V, Hamilton C, Pott TR, Samuelson CG, Friedman M. Diagnosis of obstructive sleep apnea by peripheral arterial tonometry: meta-analysis. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1343-1350. doi:10.1001/jamaoto.2013.5338. 2. Cho YW, Kim KT, Moon H, et al. Comorbid insomnia with obstructive sleep apnea: clinical characteristics and risk factors. J Clin Sleep Med. 2018;14(3):409-417. 3. Philip P, Bioulac S, Altena E, et al. Specic insomnia symptoms and self-ecacy explain CPAP compliance in a sample of OSAS patients. PLoS ONE. 2018;13(4): e0195343. https://doi.org/10.1371/journal.pone.0195343. 4. Ong JC, Crawford MR. Insomnia and obstructive sleep apnea. Sleep Med Clin. 2013;8(3):389-398. doi:10.1016/j.jsmc.2013.04.004. 5. Bjornsdottir E, Keenan BT, Eysteinsdottir B, et al. Quality of life among untreated sleep apnea patients compared to the general population and changes after treatment with positive airway pressure. J Sleep Res. 2015;24(3):328-338. doi:10.1111/jsr.12262. 6. Punjabi NM, Patil S, Crainiceanu C, Aurora RN. Variability and misclassication of sleep apnea severity based on multi-night testing. Chest. 2020;158(1):365-373. 7. Chami HA, et al. Sleepiness, quality of life, and sleep maintenance in REM versus non-REM sleep-disordered breathing. Am J Respir Crit Care Med. 2010;181(9):997-1002. 8. Schutte – Rodin, et al. Comparison of AHI using recording time versus sleep time (abstract). J Sleep. 2014;(suppl):A373. 9. Singh J. Basics of central sleep apnea. https://www.acc.org/latest-in-cardiology/articles/2014/07/22/08/25/basics-of-central-sleep-apnea. Accessed June 3, 2021.
This material is subject to a disclaimer available here.
When using the marks in our publications and this website, we used the appropriate ™, ℠, or ®. The ® symbol is used to indicate registrations in the U.S. and the territories listed in https://www.itamar-medical.com/terms-and-conditions/ and this should not mean that such trademarks are necessarily registered in other countries. For example, WatchPAT® is a trademark of Itamar Medical Ltd., registered in the U.S. and the applicable territories listed in https://www.itamar-medical.com/terms-and-conditions/ only.
WatchPAT® and PAT® are trademarks of Itamar Medical, Ltd. Copyright © 2021 by Itamar Medical, Ltd. All rights reserved.